$LUMO
Lumos Pharma Inc

2020 Q1 Form 10-K Financial Statement

#000112623420000018 Filed on March 03, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q4 2019 Q2
Revenue $21.00K $433.0K $0.00
YoY Change 114.36% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.300M $1.100M $700.0K
YoY Change 371.43% -79.63% -91.14%
% of Gross Profit
Research & Development $1.905M $2.400M $1.881M
YoY Change 30.93% -57.89% -84.44%
% of Gross Profit
Depreciation & Amortization $9.000K $1.600M $0.00
YoY Change 12.5% 700.0% -100.0%
% of Gross Profit
Operating Expenses $5.236M $3.500M $2.595M
YoY Change 144.9% -68.47% -87.03%
Operating Profit -$5.215M -$8.689M -$2.595M
YoY Change 143.92% -20.62% -85.38%
Interest Expense $48.00K $400.0K $0.00
YoY Change -20.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $92.00K $0.00 $26.00K
YoY Change 178.79% -100.0% -94.02%
Pretax Income -$5.123M -$8.300M -$2.569M
YoY Change 143.37% -20.95% -85.16%
Income Tax -$5.463M $0.00 $0.00
% Of Pretax Income
Net Earnings $340.0K -$8.271M -$2.569M
YoY Change -116.15% -21.74% -85.16%
Net Earnings / Revenue 1619.05% -1910.16%
Basic Earnings Per Share -$0.22 -$0.27
Diluted Earnings Per Share $136.4K -$2.024M -$2.000M
COMMON SHARES
Basic Shares Outstanding 37.33M shares 37.31M shares 37.28M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q4 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $85.80M $5.000M $105.4M
YoY Change -24.2% -95.86% -23.12%
Cash & Equivalents $85.82M $5.000M $105.4M
Short-Term Investments
Other Short-Term Assets $2.300M $100.0K $4.000M
YoY Change -47.73% -98.18% -23.08%
Inventory
Prepaid Expenses
Receivables
Other Receivables $355.0K $35.00K $458.0K
Total Short-Term Assets $93.16M $5.069M $110.2M
YoY Change -21.24% -96.01% -23.2%
LONG-TERM ASSETS
Property, Plant & Equipment $1.064M $84.00K $3.314M
YoY Change -69.77% -97.75% -24.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $87.90M $0.00
YoY Change
Total Long-Term Assets $89.80M $457.0K $10.61M
YoY Change 716.77% -88.18% 134.44%
TOTAL ASSETS
Total Short-Term Assets $93.16M $5.069M $110.2M
Total Long-Term Assets $89.80M $457.0K $10.61M
Total Assets $183.0M $5.526M $120.8M
YoY Change 41.53% -95.78% -18.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.362M $365.0K $689.0K
YoY Change 163.62% -34.23% -90.61%
Accrued Expenses $7.732M $709.0K $7.235M
YoY Change 11.25% -91.29% -15.15%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $100.0K
YoY Change -100.0% -100.0% 0.0%
Total Short-Term Liabilities $46.77M $1.263M $8.628M
YoY Change 427.13% -85.72% -46.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $6.100M $200.0K $13.50M
YoY Change -54.48% -97.1% 92.86%
Total Long-Term Liabilities $14.65M $191.0K $13.50M
YoY Change 9.49% -97.25% 92.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.77M $1.263M $8.628M
Total Long-Term Liabilities $14.65M $191.0K $13.50M
Total Liabilities $61.42M $1.454M $22.12M
YoY Change 176.01% -90.8% -4.09%
SHAREHOLDERS EQUITY
Retained Earnings -$59.99M -$59.68M -$311.2M
YoY Change -80.07% -79.49% 13.97%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00 $1.450M
YoY Change -100.0% 3.2%
Treasury Stock Shares 176.6K shares 112.1K shares
Shareholders Equity $121.5M -$59.46M -$53.01M
YoY Change
Total Liabilities & Shareholders Equity $183.0M $5.526M $120.8M
YoY Change 41.53% -95.78% -18.38%

Cashflow Statement

Concept 2020 Q1 2019 Q4 2019 Q2
OPERATING ACTIVITIES
Net Income $340.0K -$8.271M -$2.569M
YoY Change -116.15% -21.74% -85.16%
Depreciation, Depletion And Amortization $9.000K $1.600M $0.00
YoY Change 12.5% 700.0% -100.0%
Cash From Operating Activities -$3.310M -$23.80M -$2.300M
YoY Change 51.42% 1730.77% -66.67%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $84.20M $100.0K $0.00
YoY Change
Cash From Investing Activities $84.18M $100.0K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $0.00 -100.0K 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -$3.310M -23.80M -2.300M
Cash From Investing Activities $84.18M 100.0K 0.000
Cash From Financing Activities $0.00 -100.0K 0.000
Net Change In Cash $80.87M -23.80M -2.300M
YoY Change -3799.41% 1730.77% -66.18%
FREE CASH FLOW
Cash From Operating Activities -$3.310M -$23.80M -$2.300M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$23.80M -$2.300M
YoY Change 1730.77% -66.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001126234
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019 dei Entity File Number
EntityFileNumber
001-35342
CY2019 dei Entity Registrant Name
EntityRegistrantName
NEWLINK GENETICS CORP
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
42-1491350
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
2503 South Loop Drive
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Ames
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
IA
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
50010
CY2019 dei City Area Code
CityAreaCode
515
CY2019 dei Local Phone Number
LocalPhoneNumber
296-5555
CY2019 dei Security12b Title
Security12bTitle
Common Stock, par value $0.01
CY2019 dei Trading Symbol
TradingSymbol
NLNK
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019Q2 dei Entity Public Float
EntityPublicFloat
42833809 USD
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37328425 shares
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90549000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120738000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3046000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5536000 USD
CY2019Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
69000 USD
CY2018Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
339000 USD
CY2019Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
755000 USD
CY2018Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
459000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
94419000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
127072000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1633000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3727000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
735000 USD
CY2019Q4 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
0 USD
CY2018Q4 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
140000 USD
CY2019Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
2368000 USD
CY2018Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
3867000 USD
CY2019Q4 us-gaap Assets
Assets
96787000 USD
CY2018Q4 us-gaap Assets
Assets
130939000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
475000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
555000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10198000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8139000 USD
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
11000 USD
CY2018Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0 USD
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
92000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1100000 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
43000 USD
CY2018Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
61000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11827000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8847000 USD
CY2019Q4 nlnk Deferred Government Grants Obligations Noncurrent
DeferredGovernmentGrantsObligationsNoncurrent
6000000 USD
CY2018Q4 nlnk Deferred Government Grants Obligations Noncurrent
DeferredGovernmentGrantsObligationsNoncurrent
6000000 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
0 USD
CY2018Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
43000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
82000 USD
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
906000 USD
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
6082000 USD
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
6949000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
17909000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
15796000 USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2018Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37440094 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37343547 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37325091 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37251220 shares
CY2019Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
374000 USD
CY2018Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
373000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
413959000 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
407199000 USD
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
115003 shares
CY2018Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
92327 shares
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
1454000 USD
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
1417000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-334001000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-291012000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
78878000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
115143000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
96787000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
130939000 USD
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
936000 USD
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1206000 USD
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
390000 USD
CY2019 us-gaap Revenues
Revenues
936000 USD
CY2018 us-gaap Revenues
Revenues
12474000 USD
CY2017 us-gaap Revenues
Revenues
28711000 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22205000 USD
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45694000 USD
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69866000 USD
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23865000 USD
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29218000 USD
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31726000 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
46070000 USD
CY2018 us-gaap Operating Expenses
OperatingExpenses
74912000 USD
CY2017 us-gaap Operating Expenses
OperatingExpenses
101592000 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-45134000 USD
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-62438000 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-72881000 USD
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-19000 USD
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-102000 USD
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-126000 USD
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
2226000 USD
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
2029000 USD
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
616000 USD
CY2019 us-gaap Interest Expense
InterestExpense
50000 USD
CY2018 us-gaap Interest Expense
InterestExpense
52000 USD
CY2017 us-gaap Interest Expense
InterestExpense
119000 USD
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2157000 USD
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1875000 USD
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
371000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-42977000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-60563000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-72510000 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12000 USD
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6968000 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-559000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-42989000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-53595000 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-71951000 USD
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.15
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.44
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.30
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37294505 shares
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37191262 shares
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31304309 shares
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
129466000 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18508000 USD
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
962000 USD
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
445000 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
561000 USD
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19333000 USD
CY2017 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
289000 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-71951000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
151557000 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17120000 USD
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
143000 USD
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
151000 USD
CY2018 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
275000 USD
CY2018 us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
42000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-53595000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
115143000 USD
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6722000 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6722000 USD
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
38000 USD
CY2019 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
36000 USD
CY2019 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-20000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-42989000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
78878000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-42989000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-53595000 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-71951000 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
6722000 USD
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
17120000 USD
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
18508000 USD
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1645000 USD
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1145000 USD
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1407000 USD
CY2019 nlnk Finance Lease Right Of Use Asset Amortization And Change In Operating Lease Liability
FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability
551000 USD
CY2018 nlnk Finance Lease Right Of Use Asset Amortization And Change In Operating Lease Liability
FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability
0 USD
CY2017 nlnk Finance Lease Right Of Use Asset Amortization And Change In Operating Lease Liability
FinanceLeaseRightOfUseAssetAmortizationAndChangeInOperatingLeaseLiability
0 USD
CY2019 us-gaap Asset Impairment Charges
AssetImpairmentCharges
351000 USD
CY2018 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2017 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2018 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-102000 USD
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-126000 USD
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2491000 USD
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-226000 USD
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
305000 USD
CY2019 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
296000 USD
CY2018 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-10223000 USD
CY2017 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-14350000 USD
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1979000 USD
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-13029000 USD
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-15469000 USD
CY2019 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
421000 USD
CY2018 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
17000 USD
CY2017 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
5479000 USD
CY2019 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
CY2018 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-56000 USD
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-335000 USD
CY2019 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
0 USD
CY2018 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
92000 USD
CY2017 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
91000 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30207000 USD
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37939000 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48281000 USD
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000 USD
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
43000 USD
CY2019 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
77000 USD
CY2018 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
124000 USD
CY2017 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
254000 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
77000 USD
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
117000 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
211000 USD
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
74416000 USD
CY2019 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
38000 USD
CY2018 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
294000 USD
CY2017 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1407000 USD
CY2019 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
36000 USD
CY2018 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
275000 USD
CY2017 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
289000 USD
CY2019 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
61000 USD
CY2018 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
167000 USD
CY2017 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
246000 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-59000 USD
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-148000 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75288000 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-30189000 USD
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-37970000 USD
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
27218000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
120738000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
158708000 USD
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
131490000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90549000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
120738000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
158708000 USD
CY2019 us-gaap Interest Paid Net
InterestPaidNet
4000 USD
CY2018 us-gaap Interest Paid Net
InterestPaidNet
8000 USD
CY2017 us-gaap Interest Paid Net
InterestPaidNet
15000 USD
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
15000 USD
CY2018 us-gaap Income Taxes Paid
IncomeTaxesPaid
25000 USD
CY2017 us-gaap Income Taxes Paid
IncomeTaxesPaid
643000 USD
CY2019 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
425000 USD
CY2018 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
7057000 USD
CY2017 us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
6651000 USD
CY2019 us-gaap Nature Of Operations
NatureOfOperations
Description of Business Activities<div style="text-indent:24pt;text-align:justify;margin-top:12pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation on June 4, 1999 and initiated operations in April of 2000.</span></div><div style="text-indent:24pt;text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">NewLink and its subsidiaries (the Company) are devoting substantially all of their efforts toward research and development. The Company has incurred significant losses in all years since being incorporated, except for the year ended December 31, 2014, and has never generated revenue from commercial sales of its drugs. </span></div><div style="text-indent:24pt;text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying financial statements as of and for the year ended December 31, 2019 have been prepared assuming the Company will continue as a going concern. The Company raised net proceeds of $37.6 million from its IPO, completed a follow-on offering of its common stock raising net proceeds of $49.0 million, and raised an additional $58.7 million in net proceeds from an at the market offering (ATM) prior to March 31, 2015. </span></div><div style="text-indent:24pt;text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2017, the Company sold 1,940,656 shares of its common stock under an ATM offering, with aggregate net proceeds of $19.3 million after commissions of $398,000 paid to Cantor Fitzgerald &amp; Co. (Cantor) as the placement agent, and other costs of $163,000. In October 2017, the Company sold 5,750,000 of its shares of common stock in a public offering for aggregate net proceeds of $55.2 million after underwriters' discounts, commissions and other expenses of $3.7 million. </span></div><div style="text-indent:24pt;text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's cash and cash equivalents are expected to be adequate to satisfy the Company's liquidity requirements through 2021. If available liquidity becomes insufficient to meet the Company’s operating obligations as they come due, the Company's plans include pursuing alternative funding arrangements and/or reducing expenditures as necessary to meet the Company’s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position, and may materially affect the Company’s ability to continue as a going concern.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Merger Agreement with Lumos </span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 30, 2019, we entered into an Agreement and Plan of Merger and Reorganization (as amended, the Merger Agreement) with Cyclone Merger Sub, Inc., a wholly-owned subsidiary of NewLink (the Merger Sub) and Lumos Pharma, Inc., a privately-held Delaware corporation (Lumos), pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Lumos, with Lumos surviving as our wholly-owned subsidiary (the Merger). Following the Merger, we will change our name to “Lumos Pharma, Inc.” and Lumos will change its name to a name mutually agreed upon by us and Lumos. </span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If our stockholders approve the Merger, at the effective time of the Merger (the Effective Time), each share of Lumos capital stock outstanding immediately prior to the Effective Time (excluding shares of Lumos capital stock held as treasury stock or held or owned by Lumos or Merger Sub prior to the Effective Time and shares held by Lumos stockholders who have exercised and perfected appraisal rights in accordance with Delaware law) shall be automatically converted solely into the right to receive a number of shares of our common stock equal to the amount determined pursuant to a charter amendment to Lumos’ certificate of incorporation that will be filed prior to the Effective Time, at exchange ratios applicable to each type of Lumos capital stock. Pursuant to such conversion, immediately following the Merger, former Lumos stockholders will own approximately 50% of the aggregate number of shares of our common stock issued and outstanding following the consummation of the Merger (the Post-Closing Shares), and our stockholders as of immediately prior to the Merger will own approximately 50% of the aggregate number of Post-Closing Shares. Outstanding options to purchase Lumos common stock will be assumed by us and converted into options to purchase a number of shares of our common stock at the exchange ratio applicable to exchanging shares of Lumos common stock for our common stock. </span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Merger Agreement includes customary representations, warranties and covenants made by the Company and Lumos, including covenants relating to the Company’s and Lumos’ conduct of their respective businesses between the date of signing the Merger Agreement and the closing of the Merger. Consummation of the Merger is subject to certain closing conditions, including, among other things, approval by the stockholders of the Company and Lumos. Lumos stockholders approved the Merger in September 2019. The Merger Agreement contains certain termination rights for both NewLink and Lumos, and further provides that, upon termination of the Merger Agreement under specified circumstances, NewLink or Lumos, as applicable, may be required to pay the other party a termination fee of $2.0 million. </span></div>The Merger Agreement contemplates that we will also seek approval from our stockholders to effect a reverse stock split with the split ratio to be mutually agreed to by the Company and Lumos immediately prior to the Effective Time.
CY2019Q3 us-gaap Subsidiary Or Equity Method Investee Cumulative Percentage Ownership After All Transactions
SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions
0.50
CY2019Q4 nlnk Merger Agreement Covenants Termination Fee Payable
MergerAgreementCovenantsTerminationFeePayable
2000000.0 USD
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="text-indent:13.5pt;text-align:justify;margin-top:9pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:24pt;text-align:justify;margin-top:9pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div>
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
90500000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120700000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
653000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
653000 USD
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
0.25
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P36M
CY2019Q4 nlnk Share Based Compensation Arrangement By Share Based Payment Award Premium To Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardPremiumToMarketPriceOfferingDate
1.10
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are held by financial institutions and are federally insured up to certain limits. At times, the Company’s cash and cash equivalents balance exceeds the federally insured limits. To limit the credit risk, the Company invests its excess cash primarily in high quality securities such as money market funds. The money market funds are valued based on observable Level 1 inputs.
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.05
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y2M12D
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
599000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
133000 USD
CY2019Q4 nlnk Lessee Operating Lease Liability Payments Due After Year Two
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo
0 USD
CY2018Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
732000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
25000 USD
CY2019Q4 nlnk Lessee Operating Lease Liability Unamortized Incentives
LesseeOperatingLeaseLiabilityUnamortizedIncentives
475000 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1182000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1105000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1004000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
923000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
906000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
909000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
6570000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
11417000 USD
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
575000 USD
CY2018 us-gaap Operating Lease Expense
OperatingLeaseExpense
1100000 USD
CY2017 us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000 USD
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
1100000 USD
CY2019Q3 nlnk Share Based Payment Arrangement Option Exchange Options Converted
ShareBasedPaymentArrangementOptionExchangeOptionsConverted
3914856 shares
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9423000 USD
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10712000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7790000 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6985000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1633000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3727000 USD
CY2019Q4 nlnk Common Stock Voting Rights Votesper Share
CommonStockVotingRightsVotesperShare
1 vote
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q2 nlnk Share Based Payment Arrangement Option Exchange Number Of Shares Authorized
ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorized
5849059 shares
CY2019Q3 nlnk Share Based Payment Arrangement Option Exchange Number Of Participants
ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants
45 employee
CY2019Q3 nlnk Share Based Payment Arrangement Option Exchange Number Of Participants
ShareBasedPaymentArrangementOptionExchangeNumberOfParticipants
5 director
CY2019Q3 nlnk Share Based Payment Arrangement Option Exchange Number Of Shares Authorized Converted Percent
ShareBasedPaymentArrangementOptionExchangeNumberOfSharesAuthorizedConvertedPercent
0.67
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1720341 shares
CY2019Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.77
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P7Y
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1000000.0 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6700000 USD
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17100000 USD
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18500000 USD
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2500000 USD
CY2019 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 USD
CY2018 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 USD
CY2017 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 USD
CY2019Q4 nlnk Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Intrinsic Value Per Share
SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValuePerShare
2.53
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2000000.0 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax
DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax
140000 USD
CY2019Q4 nlnk Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax Noncurrent
DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTaxNoncurrent
69000 USD
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0 USD
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
12000 USD
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
12000 USD
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
12000 USD
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12000 USD
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 USD
CY2018 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0 USD
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-6968000 USD
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2018 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-6968000 USD
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-6968000 USD
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6968000 USD
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-332000 USD
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-140000 USD
CY2017 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
-472000 USD
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-87000 USD
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
-87000 USD
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-419000 USD
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-140000 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-559000 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
26078000 USD
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
18165000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
28990000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
28283000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2704000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
14150000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
112000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
300000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
918000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
680000 USD
CY2019Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
17000 USD
CY2018Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
15000 USD
CY2019Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
643000 USD
CY2018Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
417000 USD
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
59462000 USD
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
62010000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
59462000 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
62010000 USD
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
59500000 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
62000000.0 USD
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2500000 USD
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
11800000 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3500
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0608
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.1007
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0003
CY2019 us-gaap Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
-0.0075
CY2018 us-gaap Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
-0.0120
CY2017 us-gaap Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary
EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
-0.0736
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1527
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1820
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2410
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0107
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0016
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0280
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0003
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.1151
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0071
CY2019Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
653000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
46000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
82000 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
335000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-42989000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-53595000 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-71951000 USD
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37294505 shares
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37191262 shares
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31304309 shares
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.15
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.44
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.30
CY2019 nlnk Potential Milestone Expense
PotentialMilestoneExpense
277000 USD
CY2018 nlnk Potential Milestone Expense
PotentialMilestoneExpense
32000 USD
CY2017 nlnk Potential Milestone Expense
PotentialMilestoneExpense
1400000 USD
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
342000 USD
CY2019Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2018Q1 us-gaap Revenues
Revenues
9900000 USD
CY2018 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
261000 USD
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
361000 USD
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
55000 USD
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
303000 USD
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
401000 USD
CY2019Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.60
CY2019 us-gaap Restructuring Charges
RestructuringCharges
5600000 USD
CY2019 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
351000 USD
CY2018Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.30
CY2018 us-gaap Restructuring Charges
RestructuringCharges
1300000 USD
CY2017Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.50
CY2017 us-gaap Restructuring Charges
RestructuringCharges
1700000 USD
CY2019Q1 us-gaap Revenues
Revenues
106000 USD
CY2019Q2 us-gaap Revenues
Revenues
151000 USD
CY2019Q3 us-gaap Revenues
Revenues
246000 USD
CY2019Q4 us-gaap Revenues
Revenues
433000 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10664000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10724000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15057000 USD
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-8689000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-10036000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-10134000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-14548000 USD
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-8271000 USD
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2018Q4 us-gaap Revenues
Revenues
202000 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-18706000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17748000 USD
CY2018Q2 us-gaap Revenues
Revenues
2252000 USD
CY2018Q3 us-gaap Revenues
Revenues
120000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15038000 USD
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-10946000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-18310000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-17313000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-7403000 USD
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-10569000 USD
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2018Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28

Files In Submission

Name View Source Status
0001126234-20-000018-index-headers.html Edgar Link pending
0001126234-20-000018-index.html Edgar Link pending
0001126234-20-000018.txt Edgar Link pending
0001126234-20-000018-xbrl.zip Edgar Link pending
a2019123110kex1025.htm Edgar Link pending
a20191231q4-ex211.htm Edgar Link pending
a20191231q4-ex231.htm Edgar Link pending
a20191231q4-ex311.htm Edgar Link pending
a20191231q4-ex312.htm Edgar Link pending
a20191231q4-ex321.htm Edgar Link pending
a20191231q410kex44.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image21.gif Edgar Link pending
MetaLinks.json Edgar Link pending
newlinkexhibit1025to1i.gif Edgar Link pending
newlinkexhibit1025to1i.jpg Edgar Link pending
newlinkexhibit1025to1i1.gif Edgar Link pending
nlnk-20191231.htm Edgar Link pending
nlnk-20191231.xsd Edgar Link pending
nlnk-20191231_cal.xml Edgar Link unprocessable
nlnk-20191231_def.xml Edgar Link unprocessable
nlnk-20191231_g1.jpg Edgar Link pending
nlnk-20191231_g2.jpg Edgar Link pending
nlnk-20191231_htm.xml Edgar Link completed
nlnk-20191231_lab.xml Edgar Link unprocessable
nlnk-20191231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending